Early Prediction of Therapy Response in Patients with Acute Myeloid Leukemia by Nucleosomal DNA Fragments

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2006 Jun 1

PMID 16734907

Citations 15

Authors

Susanne Mueller

Stefan Holdenrieder

Petra Stieber

Torsten Haferlach

Andreas Schalhorn

Jan Braess

Dorothea Nagel

Dietrich Seidel

Affiliations

Soon will be listed here.

Abstract

Background: Elevated levels of nucleosomal DNA fragments can be detected in plasma and sera of patients with malignant diseases.

Methods: We investigated the course of nucleosomal DNA, thymidine kinase, lactate dehydrogenase and leukocytes in sera of 25 patients with acute myeloid leukemia during the first cycle of induction chemotherapy and tested their power to distinguish between patients with complete remission and those with no remission.

Results: Almost all patients showed strongly decreasing levels of nucleosomal DNA during the first week, in some cases after initial peaks. In overall analysis of variance, DNA levels could clearly distinguish between patients with complete remission, who had higher DNA values, and those with insufficient response (p = 0.017). The area under the curve of DNA values of days 2-4 after start of therapy (AUC 2-4) discriminated between both groups with a sensitivity of 56% at a specificity of 100%. Further, pretherapeutic levels and AUC 2-4 of nucleosomal DNA correlated significantly with blast reduction after 16 days. A tendency to higher levels in patients with complete response was also found for thymidine kinase, lactate dehydrogenase and leukocytes, however the difference did not reach the level of significance (p = 0.542, p = 0.260, and p = 0.144, respectively).

Conclusion: Our results indicate that nucleosomal DNA fragments are valuable markers for the early prediction of therapeutic efficacy in patients with acute myeloid leukemia.

Citing Articles

Early prognosis prediction in acute myeloid and acute lymphoid leukemia patients using cell-free DNA concentration ratios.

George N, Rishi B, Singh A, Vishmaya S, Kumar R, Kushwaha N Front Mol Biosci. 2024; 10:1333943.

PMID: 38317776 PMC: 10840420. DOI: 10.3389/fmolb.2023.1333943.

Modeling early treatment response in AML from cell-free tumor DNA.

Wang D, Rausch C, Buerger S, Tschuri S, Rothenberg-Thurley M, Schulz M iScience. 2023; 26(12):108271.

PMID: 38047080 PMC: 10690559. DOI: 10.1016/j.isci.2023.108271.

Epigenetic profiles of elevated cell free circulating H3.1 nucleosomes as potential biomarkers for non-Hodgkin lymphoma.

Van Den Ackerveken P, Lobbens A, Pamart D, Kotronoulas A, Rommelaere G, Eccleston M Sci Rep. 2023; 13(1):16335.

PMID: 37770512 PMC: 10539380. DOI: 10.1038/s41598-023-43520-0.

Liquid biopsies and minimal residual disease in myeloid malignancies.

Allam S, Nasr K, Khalid F, Shah Z, Khan Suheb M, Mulla S Front Oncol. 2023; 13:1164017.

PMID: 37213280 PMC: 10196237. DOI: 10.3389/fonc.2023.1164017.

Circulating Histones to Detect and Monitor the Progression of Cancer.

Tsoneva D, Ivanov M, Conev N, Manev R, Stoyanov D, Vinciguerra M Int J Mol Sci. 2023; 24(2).

PMID: 36674455 PMC: 9860657. DOI: 10.3390/ijms24020942.

References

Johnson P, Lo Y . Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem. 2002; 48(8):1186-93. View

Petak I, HOUGHTON J . Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res. 2001; 7(2):95-106. DOI: 10.1007/BF03032574. View

Ng E, Tsui N, Lam N, Chiu R, Yu S, Wong S . Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem. 2002; 48(8):1212-7. View

Repp R, Schaekel U, Helm G, Thiede C, Soucek S, Pascheberg U . Immunophenotyping is an independent factor for risk stratification in AML. Cytometry B Clin Cytom. 2003; 53(1):11-9. DOI: 10.1002/cyto.b.10030. View

Lo Y, Tein M, Pang C, Yeung C, Tong K, Hjelm N . Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet. 1998; 351(9112):1329-30. DOI: 10.1016/s0140-6736(05)79055-3. View

KERR J, Winterford C, Harmon B . Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994; 73(8):2013-26. DOI: 10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j. View

Braess J, Schneiderat P, Schoch C, Fiegl M, Lorenz I, Hiddemann W . Functional analysis of apoptosis induction in acute myeloid leukaemia-relevance of karyotype and clinical treatment response. Br J Haematol. 2004; 126(3):338-47. DOI: 10.1111/j.1365-2141.2004.05039.x. View

Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K . Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004; 10(18 Pt 1):5981-7. DOI: 10.1158/1078-0432.CCR-04-0625. View

Rumore P, Muralidhar B, Lin M, Lai C, Steinman C . Haemodialysis as a model for studying endogenous plasma DNA: oligonucleosome-like structure and clearance. Clin Exp Immunol. 1992; 90(1):56-62. PMC: 1554541. DOI: 10.1111/j.1365-2249.1992.tb05831.x. View

10.

Holdenrieder S, Stieber P, Bodenmuller H, Busch M, von Pawel J, Schalhorn A . Circulating nucleosomes in serum. Ann N Y Acad Sci. 2001; 945:93-102. DOI: 10.1111/j.1749-6632.2001.tb03869.x. View

11.

Holdenrieder S, Stieber P, Bodenmuller H, Busch M, Fertig G, Furst H . Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer. 2001; 95(2):114-20. DOI: 10.1002/1097-0215(20010320)95:2<114::aid-ijc1020>3.0.co;2-q. View

12.

Holdenrieder S, Stieber P, Bodenmuller H, Fertig G, Furst H, Schmeller N . Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med. 2001; 39(7):596-605. DOI: 10.1515/CCLM.2001.095. View

13.

Holdenrieder S, Stieber P, Forg T, Kuhl M, Schulz L, Busch M . Apoptosis in serum of patients with solid tumours. Anticancer Res. 1999; 19(4A):2721-4. View

14.

Kuroi K, Tanaka C, Toi M . Clinical significance of plasma nucleosome levels in cancer patients. Int J Oncol. 2001; 19(1):143-8. DOI: 10.3892/ijo.19.1.143. View

15.

Au W, Pang A, Choy C, Chim C, Kwong Y . Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004; 104(1):243-9. DOI: 10.1182/blood-2003-12-4197. View

16.

Barry M, Behnke C, Eastman A . Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol. 1990; 40(10):2353-62. DOI: 10.1016/0006-2952(90)90733-2. View

17.

Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C . Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 2003; 21(21):3902-8. DOI: 10.1200/JCO.2003.02.006. View

18.

Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M . p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998; 188(11):2033-45. PMC: 2212386. DOI: 10.1084/jem.188.11.2033. View

19.

Sozzi G, Conte D, Mariani L, Vullo S, Roz L, Lombardo C . Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2001; 61(12):4675-8. View

20.

Ferrara F . Unanswered questions in acute myeloid leukaemia. Lancet Oncol. 2004; 5(7):443-50. DOI: 10.1016/S1470-2045(04)01512-8. View